Idevax Announces CE Marking for VAX-ID Intradermal Drug Delivery Device
Antwerp, Belgium – April 14, 2025 – Idevax, a pioneering medical device company specializing in innovative skin drug delivery solutions, today announced that its flagship product, VAX-ID®, has received CE marking as a Class IIa medical device. This significant milestone confirms that VAX-ID® meets the stringent European Medical Device Regulations for products sold within the European Economic Area (EEA).
VAX-ID® is an award-winning, patented device platform designed for easy, safe and reliable intradermal injection, making it a groundbreaking solution for the administration of vaccines and other medications. As the dermal layer of the skin is densely populated with immune cells, it’s considered an optimal site for drug delivery. With its user-friendly design and high precision, VAX-ID® aims to improve comfort for patients and vaccinees and simplify the drug delivery process.
Vanessa Vankerckhoven, CEO of Idevax, expressed her excitement about this achievement: “Obtaining CE marking for VAX-ID® is a testament to our team’s dedication and innovation. This milestone brings us one step closer to making reliable drug delivery accessible to more people across Europe. We are committed to advancing healthcare through cutting-edge technology.”
Koen Beyers, CTO of Idevax, added: “The CE marking is a significant validation of the quality and safety of our VAX-ID® device. It reflects our commitment to meeting the highest standards in medical technology and proves that smart hardware design optimized for massive upscaling has true market potential. We look forward to expanding our reach and making a positive impact on global health.”
The CE marking, issued by ECM, allows Idevax to market and distribute VAX-ID® throughout the EEA, providing healthcare professionals with a new tool to enhance patient care. This achievement underscores Idevax’s commitment to innovation and excellence in the medical device industry.
For more information about VAX-ID® and Idevax, please visit Idevax’s website.
Contact:
Vanessa Vankerckhoven – Founder & CEO –Vanessa.vankerckhoven@idevax.com – +32486761885
About Idevax
Idevax is a pioneering medical device company based in Antwerp and Wijnegem, Flanders, Belgium. Founded in 2020 by Vanessa Vankerckhoven and Koen Beyers, Idevax is an ISO13485-certified company dedicated to developing, producing, and commercializing innovative precision drug delivery devices. The company’s mission is to enable reliable skin drug delivery and enhance patient comfort through cutting-edge solutions and commitment to excellence. The VAX-ID® device platform has CE mark to deliver medications and vaccines intradermally. The devices are safe, accurate, easy to use by healthcare professionals and offer patient comfort. They can improve vaccine effectiveness and offer dose-sparing potential.
For more information or if you are interested in partnering with us, check out our website or contact us. Follow us on LinkedIn.
